A new analysis of patients treated with Kite’s Yescarta (axi-cel) identified genetic signatures linked to toxicity risk, published in Science Immunology. Researchers led by Mark Leick at Massachusetts General Hospital, using data from Zuma-1 and Zuma-7, highlighted mutations affecting STXBP2 in a subset of patients and pointed to pathways that may help guide future CAR-T engineering toward safer profiles.